Table 5:

Reduction achieved with the dose-reduction platform in comparison with the reference platform^{^a}

Procedure	CP_KA (Gy × cm²)	Fluoroscopy Duration (min)	Contrast Volume (mL)
Diagnostic	88.2 (63.3%)^{^b}	−1.7 (−17.3%)^{^c}	−12.6 (−8.3%)
All interventions	171.8 (52.7%)^{^b}	−5.9 (−16.6)	−23.1 (−10.1%)
Coil embolization	166.3 (50.3%)^{^b}	−4.4 (−10.3%)	−37.3 (−13.7%)
Flow diverter	82.1 (30.5%)^{^c}	−14.9 (−55.1%)^{^c}	−34.6 (−15.5%)
Vasospasm	124.9 (71.1%)^{^b}	1.7 (11.1%)	9.4 (6.2%)
Thrombectomy	191.9 (60.2%)^{^b}	−5.1 (−17.8%)	2.9 (1.4%)
Stent-assisted coiling	112.1 (35.2%)^{^c}	−11.1 (−26.2%)	−72.6 (−27.1%)^{^c}
Carotid stenting	122.2 (55.7%)^{^b}	−1.7 (−6.7%)	17.6 (7.9%)
Epistaxis	251.0 (73.8%^{^b}	−7.4 (−22.7%)	73.7 (30.2%)
AVM	165.4 (26.2%)	−8.9 (−8.7%)	−105.3 (−43.2%)^{^c}
AVF	222.4 (37.6%)	−24.9 (−36.2%)	−51.3 (−15.6%)
Overall	160.3 (53.2%)^{^b}	−5.2 (−16.8%)^{^c}	−15.3 (−6.7%)

↵a Positive values indicate a reduction with the dose-reduction platform. Differences (percentage) in cumulative dose-area product, total fluoroscopy duration, and administered contrast volume were obtained from least squares means.
↵b P < .0001.
↵c P < .05.